Evidence map›Paper›PMID 36275801›Full record

ArticleFrontiers in medicine2022

Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease.

Gary E Gibson, Howard H Feldman, Sheng Zhang, Sarah A Flowers, José A Luchsinger

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Reinforcing Nrf2 Signaling: Help in the Alzheimer's Disease Context.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Adolescent Alcohol and the Spectrum of Cognitive Dysfunction in Aging.Advances in experimental medicine and biology · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Gary E GibsonWeill Cornell Medicine, Brain and Mind Research Institute, Burke Neurological Institute, White Plains, NY, United States.
Howard H FeldmanAlzheimer's Disease Cooperative Study and Department of Neurosciences, University of California, San Diego, San Diego, CA, United States.
Sheng ZhangProteomics and Metabolomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY, United States.
Sarah A FlowersDepartment of Neuroscience, Georgetown University, Washington, DC, United States.
José A LuchsingerDepartments of Medicine and Epidemiology, Columbia University Irving Medical Center, New York, NY, United States.
Burke Medical Research Institute · USColumbia University Irving Medical Center · USCornell University · USGeorgetown University · USUniversity of California, San Diego · US

Funding

Phase II randomized controlled trial of benfotiamine in early Alzheimer's DiseaseR01AG076634 · NIA · WINIFRED MASTERSON BURKE MED RES INST · PI Howard Feldman, GARY E GIBSON · 2022 to 2026
$38.8M
Apolipoprotein E glycosylation and its role in Alzheimer's disease pathogenesisR01AG072505 · NIA · UNIVERSITY OF VIRGINIA · PI FLOWERS, SARAH ANN · 2021 to 2025
$2.7M
Midcareer Award for Research in Dementia Risk Factors and PreventionK24AG045334 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jose Alejandro Luchsinger · 2016 to 2026
$1.5M
NIA NIH HHS K24 AG045334NIA NIH HHS R01 AG072505NIA NIH HHS R01 AG076634
6 · The paper itself

Abstract

of the study.

Indexed as

Advanced Glycation Endproducts (AGE)Alzheimer's diseasebenfotiaminecognitionglucose metabolismtherapythiamine

Identifiers

PMID36275801
PMCPMC9585656
OpenAlexW4300818867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.